Kell Østerlind

7.7k total citations · 2 hit papers
106 papers, 5.9k citations indexed

About

Kell Østerlind is a scholar working on Oncology, Epidemiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Kell Østerlind has authored 106 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 43 papers in Epidemiology and 37 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Kell Østerlind's work include Lung Cancer Research Studies (51 papers), Neuroendocrine Tumor Research Advances (42 papers) and Lung Cancer Treatments and Mutations (20 papers). Kell Østerlind is often cited by papers focused on Lung Cancer Research Studies (51 papers), Neuroendocrine Tumor Research Advances (42 papers) and Lung Cancer Treatments and Mutations (20 papers). Kell Østerlind collaborates with scholars based in Denmark, United States and United Kingdom. Kell Østerlind's co-authors include Heine H. Hansen, P Dombernowsky, Jørgen Gliemann, J. Vinten, Per Kragh Andersen, Fred R. Hirsch, M Hansen, Steen Gammeltoft, Daniel C. Ihde and Ola Brodin and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Kell Østerlind

101 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

2008 1.0k citations Kell Østerlind et al. profile →
A Meta-Analysis of Thoracic Radiotherapy for Small-Cell Lung Cancer

1992 932 citations Kell Østerlind et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kell Østerlind Denmark	38	4.1k	2.5k	2.0k	1.5k	801	106	5.9k
P Dombernowsky Denmark	45	4.4k 1.1×	2.1k 0.8×	1.4k 0.7×	1.6k 1.0×	1.3k 1.6×	195	6.7k
Hiroshi Ueoka Japan	37	4.2k 1.0×	3.7k 1.5×	1.2k 0.6×	1.7k 1.1×	501 0.6×	212	6.5k
Randolph S. Marks United States	41	2.7k 0.7×	2.8k 1.1×	989 0.5×	1.4k 0.9×	518 0.6×	121	5.9k
Anders Mellemgaard Denmark	41	4.1k 1.0×	4.6k 1.8×	994 0.5×	1.9k 1.3×	1.1k 1.4×	144	7.6k
Hideo Kunitoh Japan	43	3.5k 0.8×	3.5k 1.4×	655 0.3×	2.0k 1.3×	1.1k 1.4×	217	6.5k
Kaoru Kubota Japan	44	4.4k 1.1×	3.7k 1.5×	767 0.4×	1.5k 1.0×	740 0.9×	269	7.1k
Vittorio Gebbia Italy	40	4.2k 1.0×	2.2k 0.9×	627 0.3×	1.0k 0.7×	1.0k 1.3×	290	7.0k
Ikuo Sekine Japan	38	3.3k 0.8×	3.0k 1.2×	743 0.4×	1.3k 0.8×	742 0.9×	228	5.8k
Philip Bonomi United States	42	4.9k 1.2×	4.4k 1.8×	652 0.3×	2.1k 1.4×	978 1.2×	241	8.0k
Alan B. Sandler United States	44	4.5k 1.1×	3.7k 1.5×	554 0.3×	2.4k 1.6×	1.0k 1.3×	109	7.5k

Countries citing papers authored by Kell Østerlind

Since Specialization

Citations

This map shows the geographic impact of Kell Østerlind's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kell Østerlind with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kell Østerlind more than expected).

Fields of papers citing papers by Kell Østerlind

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kell Østerlind. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kell Østerlind. The network helps show where Kell Østerlind may publish in the future.

Co-authorship network of co-authors of Kell Østerlind

This figure shows the co-authorship network connecting the top 25 collaborators of Kell Østerlind. A scholar is included among the top collaborators of Kell Østerlind based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kell Østerlind. Kell Østerlind is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eefsen, Rikke Løvendahl, Jim S. Larsen, Louise Laurberg Klarskov, et al.. (2023). Therapy with pembrolizumab in treatment‐naïve patients with nonmetastatic, mismatch repair deficient colorectal cancer. International Journal of Cancer. 152(10). 2145–2152. 9 indexed citations

Fristrup, Claus Wilki, Benny Vittrup Jensen, Per Pfeiffer, et al.. (2021). Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age. Pancreas. 50(5). 685–695. 3 indexed citations

Fristrup, Claus Wilki, Benny Vittrup Jensen, Per Pfeiffer, et al.. (2020). Initial treatment and survival in 4163 Danish patients with pancreatic cancer: A nationwide unselected real-world register study. European Journal of Cancer. 129. 50–59. 15 indexed citations

Schmidt, Nina, Grith Møller, Lene Bæksgaard, et al.. (2020). Fish oil supplementation in cancer patients. Capsules or nutritional drink supplements? A controlled study of compliance. Clinical Nutrition ESPEN. 35. 63–68. 20 indexed citations

Ladekarl, Morten, Per Pfeiffer, Mette Yilmaz, et al.. (2019). The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study. Acta Oncologica. 58(6). 864–871. 20 indexed citations

Rossing, Mary Anne, Oľga Østrup, Peter Nørgaard Larsen, et al.. (2018). Genomic alterations accompanying tumour evolution in colorectal cancer: tracking the differences between primary tumours and synchronous liver metastases by whole-exome sequencing. BMC Cancer. 18(1). 752–752. 28 indexed citations

Dalton, Susanne Oksbjerg, Marianne Steding‐Jessen, Erik Jakobsen, et al.. (2015). Socioeconomic position and survival after lung cancer: Influence of stage, treatment and comorbidity among Danish patients with lung cancer diagnosed in 2004–2010. Acta Oncologica. 54(5). 797–804. 51 indexed citations

Eefsen, Rikke Løvendahl, Lars H. Engelholm, Warner Alpízar‐Alpízar, et al.. (2015). Inflammation and uPAR-Expression in Colorectal Liver Metastases in Relation to Growth Pattern and Neo-adjuvant Therapy. Cancer Microenvironment. 8(2). 93–100. 16 indexed citations

Boisen, Mogens K., Julia S. Johansen, Christian Dehlendorff, et al.. (2013). Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Annals of Oncology. 24(10). 2554–2559. 76 indexed citations

10.

Jakobsen, Erik, Anders Green, Kell Østerlind, & Torben Palshof. (2012). Dansk Lunge Cancer Register. Ugeskrift for Læger. 174(42).

11.

Østerlind, Kell, et al.. (2011). Successful Twin Pregnancy Outcome After In Utero Exposure to FOLFOX for Metastatic Colon Cancer: A Case Report and Review of the Literature. Clinical Colorectal Cancer. 10(4). 348–352. 28 indexed citations

12.

Jensen, Lars Henrik, et al.. (2008). Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer. 62(1). 85–91. 43 indexed citations

13.

Dziadziuszko, Rafał, Bente Holm, Kell Østerlind, et al.. (2006). Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy. Annals of Oncology. 18(3). 447–452. 37 indexed citations

14.

Østerlind, Kell. (2001). Chemotherapy in small cell lung cancer. European Respiratory Journal. 18(6). 1026–1043. 23 indexed citations

15.

Lassen, Ulrik, Kell Østerlind, Fred R. Hirsch, et al.. (1999). Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression. British Journal of Cancer. 79(3-4). 515–519. 31 indexed citations

16.

Østerlind, Kell, et al.. (1996). Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. British Journal of Cancer. 74(3). 463–467. 76 indexed citations

17.

Lassen, Ulrik, Kell Østerlind, M Hansen, et al.. (1995). Long-term survival in small-cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years--an analysis of 1,714 consecutive patients.. Journal of Clinical Oncology. 13(5). 1215–1220. 209 indexed citations

18.

Østerlind, Kell, et al.. (1992). Serum neuron specific enolase (NSE) is a determinant of response duration in small cell lung cancer (SCLC). British Journal of Cancer. 66(3). 594–598. 17 indexed citations

19.

Østerlind, Kell, M Hansen, Fred R. Hirsch, et al.. (1991). Combination chemotheraphy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens. Annals of Oncology. 2(1). 41–46. 11 indexed citations

20.

Sørensen, Jens Benn, et al.. (1987). Syndrome of Inappropriate Antidiuresis in Small‐Cell Lung Cancer. Acta Medica Scandinavica. 222(2). 155–161. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact